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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder with few biomarkers even though it 
impacts a relatively large portion of the population and is predicted to affect significantly more 
individuals in the future. Neuroimaging has been used in concert with genetic information to 
improve our understanding in relation to how AD arises and how it can be potentially diagnosed. 
Additionally, evidence suggests synonymous variants can have a functional impact on gene 
regulatory mechanisms, including those related to AD. Some synonymous codons are preferred 
over others leading to a codon bias. The bias can arise with respect to codons that are more or less 
frequently used in the genome. A bias can also result from optimal and non-optimal codons, which 
have stronger and weaker codon anti-codon interactions, respectively. Although association tests 
have been utilized before to identify genes associated with AD, it remains unclear how codon bias 
plays a role and if it can improve rare variant analysis. In this work, rare variants from whole-
genome sequencing from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort were 
binned into genes using BioBin. An association analysis of the genes with AD-related 
neuroimaging biomarker was performed using SKAT-O. While using all synonymous variants we 
did not identify any genome-wide significant associations, using only synonymous variants that 
affected codon frequency we identified several genes as significantly associated with the imaging 
phenotype. Additionally, significant associations were found using only rare variants that contains 
an optimal codon in among minor alleles and a non-optimal codon in the major allele. These 
results suggest that codon bias may play a role in AD and that it can be used to improve detection 
power in rare variant association analysis.
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1. Introduction
Rare and low-frequency variants have a significant influence on the heritability of disease. 
Rare variants are often spurious; thus, it can be difficult to run an association test on an 
individual locus because it will be underpowered [1]. In order to overcome this issue, rare 
variants can be grouped or “binned” together based on prior biological knowledge related to 
the genetic etiology of the disease [2–4]. For instance, rare variants can be binned into 
genes, pathways, intergenic, conserved regions, or any other defined region of the genome 
[3, 5]. This strategy has several strengths: first it increases the detection power by 
aggregating association signals in the variants in the bin; secondly, it reduces the multiple 
testing burden by not testing every variant, thus increasing the power to detect a significant 
association. In addition to binning by a specific region, filtering for a specific type of variant, 
such as non-synonymous changes, have important benefits in addition to reducing the testing 
burden by focusing the association on variants that are more likely to influence the 
phenotype and provide easier interpretation of the results [6].
Synonymous mutations represent a change in the coding sequencing at the nucleotide level 
without changing the amino acid sequence. Since multiple codons code for the same amino 
acid, the genetic code is called “degenerate”. It is likely that these characteristics of the 
genome is partially responsible for leading investigators to the assumption that synonymous 
mutations and variants have little to no impact on the protein, and are thus often dubbed 
“silent” without further investigation. However, it has been shown that different organisms 
prefer some codons over others and codon usage can also vary between genes in the same 
organism, suggesting there has been evolutionary pressure to optimize synonymous codons 
[7, 8]. Further investigation has demonstrated the many gene regulatory mechanisms by 
which codon bias can impart its affects such as splicing, RNA secondary structure, and 
translation [9, 10]. Moreover, synonymous variants have been implicated in a number of 
diseases including neurological, immune, cancer, blood-related, heart, and others [9]. The 
synonymous variants associated with these diseases are attributed to multiple mechanisms, 
therefore it will be important to study multiple forms of codon bias.
There are a number of ways in which codon usage can be biased and thus measured (Figure 
1). For instance, the relative synonymous codon usage (RSCU) score represents the 
frequency for which the codon is used relative to other synonymous codons, thus providing a 
metric for determining whether a mutation replaces a more common codon with a rarer 
codon or vice versa [9, 11]. Substituting rare and common synonymous codons can affect 
translation and protein activity in vitro [12]. Both single cellular and multicellular eukaryotic 
organisms utilize codons that use rare and common tRNAs at the beginning and end of the 
gene, respectively, to impart control over translation rates [13]. Another means by which 
codon bias has been observed is through codon optimality. Some codons are more optimal 
Miller et al. Page 2
Pac Symp Biocomput. Author manuscript; available in PMC 2018 January 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
than others by having stronger interactions with their cognate tRNA, or having more tRNAs 
available resulting in translation proceeding with less pausing and with higher fidelity, and in 
some cases affecting the stability of the mRNA [14].
In this study, we identified synonymous rare variants that have a functional impact on gene 
regulatory mechanisms in whole genome sequencing data from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort and then performed an association analysis of the 
functional synonymous variants with AD-related neuroimaging biomarker. AD is a 
progressive neurodegenerative disorder. Currently AD has no cure or preventive therapy. 
Genetic risk clearly plays an important role in AD and neuroimaging has been used in 
concert with genetic information to improve our understanding in relation to how AD arises 
and how it can be potentially diagnosed.
2. Methods
2.1. Study sample
Data (whole genome sequencing and MRI imaging) used in this study were obtained from 
the ADNI database (http://adni.loni.usc.edu/). Samples were collected as described 
previously [6]. There was a total of 750 non-Hispanic Caucasian participants (425 were male 
and 325 female). The average age and years of education was 73.1 +/− 7.0 and 16.1 +/− 2.8 
years, respectively.
2.2. Neuroimaging analysis
Pre-processed baseline 1.5T and 3T MRI scans were downloaded from the ADNI and T1-
weighted brain MRI scans were processed using previously described automated MRI 
analysis technique, FreeSurfer software, which was used to extract mean bilateral entorhinal 
cortical thickness and total intracranial volume (ICV) [15]. Mean entorhinal cortical 
thickness, AD-related neuroimaging biomarker, was used as endophenotype for the 
association analysis.
2.3. Variant annotation
750 ADNI non-Hispanic Caucasian participants with baseline MRI scans and whole-genome 
sequencing (WGS) were used in this study. The VCFs containing the genomic information 
for these 750 individuals were annotated using the variant effect predictor (VEP) software 
package. Using VEP, “synonymous” variants were selected using the filter function. Codons 
were then annotated as either optimal or non-optimal based on previous studies that 
characterized the codon anti-codon affinities [16–18]. The transition from optimal (O) to 
non-optimal (NO) was defined as the most common allele was O and the alternate allele was 
NO, and the reciprocal is true for the NO to O variants. Additionally, the relative 
synonymous codon usage (RSCU) score was calculated as:
Nc refers to the frequency of a specific codon
Na is the frequency of the amino acid Nc codes for
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S represents the number of synonymous codons for Na
The codon frequencies for Homo sapiens were acquired from the Codon Usage Database 
(http://www.kazusa.or.jp/codon/). RSCU increasing was defined as the most common allele 
was in a codon with a lower RSCU score than the synonymous codon that the alternate allele 
produced. Whereas, for a decreasing RSCU score the most common allele was in a codon 
with a higher RSCU score than the synonymous codon that the alternate allele produced. 
Since only synonymous codons for the same amino acid were compared, the RSCU 
comparisons were effectively just comparing codon frequency in this work.
2.4. BioBin analysis and association test
BioBin was employed to group variants together by genic region [2–5]. BioBin uses gene 
annotations from LOKI (the library of knowledge integration), which contains information 
from several databases including but not limited to NCBI Entrez, UCSC Genome Browser, 
and Kyoto Encyclopedia of Genes and Genomes (KEGG). Only rare variants with minor 
allele frequency (MAF) less than 0.01 were binned and Madsen & Browning weighting was 
applied as previously described [5]. Association tests were performed using SKAT-O [19], 
adjusting for age, gender, years of education, intracranial volume (ICV) and MRI field 
strength as covariates. Although neuroimaging MRI scans from all ADNI participants 
included in the analysis were obtained from multiple sites, all sites followed the same ADNI 
MRI protocol and each raw scan was processed using a FreeSurfer pipeline at the Indiana 
University. Thus, the site was not included as a covariate since there is likely to be little site 
effects if any. The advantage of using SKAT-O is that it can utilize both dispersion or burden 
tests in order to detect a significant association [19]. P-values were adjusted for multiple 
tests using the p.adjust function in R, using the “FDR” method [20].
3. Results
Variants that represent a synonymous alteration were identified using VEP. The rare (MAF 
<0.01) synonymous variants were then binned based on the genes they were located in, 
using BioBin (Figure 2). Each gene was required to have at least five variants across the 
cohort to be included in the analysis. Setting a minimum bin size establishes a more 
stringent threshold for finding an association. Additionally, by having fewer bins, there will 
be fewer tests performed, thus increasing the power to detect a significant association. 
previous studies have utilized a threshold when attempting to identify significant 
associations between genes and phenotypes of interest [21]. An association test was then 
performed between the genes and the imaging phenotype (entorhinal cortical thickness) 
using SKAT-O and corrected for multiple testing. When using all synonymous variants, there 
were no genes that reached genome-wide significance (FDR < 5%) nor were there any 
suggestive of being significant (FDR < 10%) (Table. 1).
However, using only synonymous variants with decreasing RSCU scores or increasing 
RSCU scores, we identified two (MLST8 and RHOB) and six genes (FLG2, CHD6, CD244, 
FLG-AS1, SERPINB5, and GTF3C1) as significantly associated with entorhinal cortical 
thickness after multiple testing adjustment, respectively (Table 2 and Table 3). There are also 
two genes that were suggestive of being significant (Table 3). In addition, we performed a 
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detailed unbiased whole-brain surface-based analysis using multivariate regression models 
to assess the effects of synonymous rare variants in MLST8 and RHOB on whole-brain 
cortical thickness. First, we calculated a single polygenic risk score by collapsing all rare 
variants and counting minor alleles with a dominant genetic model. Figure 3 displays the 
results of the main effect of synonymous rare variants with decreasing RSCU scores in a 
surface-based whole-brain analysis. We identified highly significant clusters as associated 
with the risk scores in the entorhinal cortex after multiple comparison adjustment.
In addition, synonymous variants were separated into variants that introduce a non-optimal 
codon (O to NO) and those which introduce an optimal codon (NO to O). The results from 
each association analysis are represented in tables 4 and 5. Although no genes met genome-
wide significance using the O to NO variants, the NO to O rare variants in five genes (DTL, 
FLG2, SERPINB5, FLG-AS1, and ZNF599) were significantly associated with entorhinal 
cortical thickness after multiple comparison adjustment (FDR < 5%).
4. Discussion
Here we have performed an association analysis of synonymous rare variants from WGS 
with a functional impact on gene regulatory mechanisms with AD-related neuroimaging 
biomarker. Variants that represented synonymous changes between the codon of the major 
and minor alleles were first selected. BioBin was then used to count the number of variants 
per gene. No significant associations were identified using all synonymous variants. 
However, by focusing on specific groups, like those which affect frequency or optimality, 
significant associations were identified. In other words, by focusing on variants that are 
more likely to impact gene expression and possibly protein function, associations with genes 
that were previously undetected using all synonymous variants with AD neuroimaging 
biomarker were identified. Using all synonymous variants may be less likely to identify 
significant associations because it increases the likelihood of including synonymous variants 
that are in fact benign, thus drowning out the signal from synonymous variants that are more 
likely to be functional. Furthermore, by selecting only variants of a certain type, the number 
of tests performed was also reduced when compared to using all synonymous variants 
(compare table 1 to tables 2 through 5). With fewer association tests to run, the power to 
detect an association will also increase. The significant associations may provide useful 
insights into the biology of AD.
Several genes were associated with the imaging phenotype through variants that had a 
synonymous change which caused a change in relative codon usage. MLST8 is a subunit of 
the TOR complex which is a key regulator of the cellular growth and survival in response to 
environmental cues [22–24]. Furthermore, it was found that a SNP near MLST8 has a cis-
regulatory effect on its expression in the brain in an age dependent manner [25]. 
Interestingly, gene expression also overlapped with genes that had epigenetic signatures that 
implicated it in Alzheimer’s [25]. RHOB is a member of the Rho GTPase family of proteins 
responsible for modulating the actin cytoskeleton and gene expression [26]. RHOB is 
induced during neurotrauma which is a known risk factor for AD [27–29]. CHD6 is a 
chromatin remodeler that is a member of the SNF2/RAD54 helicase protein family with no 
recognized link to AD [30]. Although expressed in most tissues, not much is known about 
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the anti-sense FLG-ASH1 transcript (genecards.org). Thus, multiple genes that have been 
previously connected to AD were identified here along with genes that have not previously 
been found to be associated with AD, or have little known about them at all. However, even 
though some genes had been previously associated with AD, this work presents a novel 
mechanism by which those associations may have arose.
Finding associations through the unique types of codon bias sheds light on possible 
mechanisms that may be at play. Generally, more simple eukaryotes like yeast often have a 
positive correlation between codon frequency and tRNA abundance, making codon bias 
easier to dissect, however human codon bias is more complicated [31]. Thus, it was 
surprising that significant associations were identified simply by using variants that either 
increased or decreased in frequency. It has been shown that changing codons from rare to 
common can impact translation and protein activity [12]. So while there may not be as easily 
an explainable relationship between rare and common codons in humans, they may still 
impact the expression of some genes. RHOB was significantly associated with the 
phenotype using frequency and almost significant using optimality, thus another possibility 
is that frequency could be a surrogate for other types of codon bias. Codon optimality offers 
a more refined characterization in terms of why the association may exist between these 
genes and the phenotype. In this study, significant associations were found among the 
variants that went from non-optimal to optimal. More optimal codons are expected to reduce 
pausing of the ribosome on the transcript [12]. It has been suggested that ribosome pausing 
may be important for allowing the protein to properly fold before the translation continues 
[12, 32]. Codon optimality can also affect mRNA stability [14]. Thus, the variants in the 
genes with an increase in optimal codons may have altered protein activity and/or expression 
levels which may eventually reach its way to impacting the AD related phenotype.
Although it was possible to detect significant associations between the imaging phenotype 
and binned rare variants, there are a number of ways the methodology can be improved for 
future work, and are thus limitations of the methodology as it currently stands. For instance, 
it has been illustrated that codon bias can be observed when comparing the codon usages 
among highly expressed lowly expressed genes [8, 33, 34]. Currently, the method employed 
here is not be able to address such complex mechanisms. Thus, future analysis could divide 
codon bias among highly or lowly expressed genes in cell types such as brain tissue. 
Another limitation of our study is the way in which we calculated codon bias, as there are 
other ways of measuring bias in terms of frequency and optimality [31, 35], so these 
calculations should also be tested for their ability to improve signal strength in a rare variant 
association test for future work. It will be important for follow-up association tests to 
replicate these findings to illustrate that the results and conclusions are robust. Of course, 
another limitation is that without experimental follow up studies it cannot be suggested that 
these variants are causal. Thus, functional validation would be incredibly valuable to 
measure empirically how codon bias mediates the relationship between these genes and the 
imaging phenotype, AD, and/or neurological diseases in general. Codon bias has also been 
investigated with respect to cancer, where non-optimal codons mutations were enriched 
among multiple types of cancers [16]. Furthermore, synonymous variants have been 
associated with a variety of disease including, but not limited to, blood-related, bone, 
immune and other neurological disorders [9], suggesting the methods utilized in this work 
Miller et al. Page 6
Pac Symp Biocomput. Author manuscript; available in PMC 2018 January 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
could contribute to our understand of a wide range of diseases. In summary, this work has 
illustrated variants that contribute to codon bias can be used to increase detection power. 
Moreover, codon bias is associated with an AD-related neuroimaging biomarker, suggesting 
synonymous variants can be used to explain the etiology of AD.
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Fig. 1. 
Codon bias effects translation of mRNA. When the ribosome translates the mRNA, it will 
come into contact with both common, rare, optimal (O), and/or non-optimal codons (NO). 
After the ribosome starts translating (top), it may come into contact with a common or 
optimal codon. These codons are likely to lead to the ribosome continuing on the mRNA. 
Rare codons or non-optimal codons (bottom figure) may lead to the ribosome pausing or 
slowing down, possibly to allow for the protein to fold correctly.
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Fig. 2. 
Variants were from ADNI were annotated using VEP. Synonymous variants were then 
annotated using optimality and RSCU score. BioBin utilized the annotation from LOKI to 
bin rare variants into genes. SKAT-O was used to test genes for an association with the 
ADNI imaging phenotype.
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Figure 3. Surface-based whole-brain analysis results
A whole-brain analysis of cortical thickness was performed to visualize the topography of 
genetic association (a) MLST8 and (b) RHOB in an unbiased manner. A threshold for 
statistical maps was set using a random field theory adjustment to a corrected significance 
level of p=0.05.
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Table 1
Top 5 associations for all synonymous variants (11,236 genes total)
Gene # of Loci p-value Corrected p-value
RHOB 4 1.14E-05 0.121
TMEM201 9 2.15E-05 0.121
MLST8 8 6.02E-05 0.212
MOB3B 4 7.56E-05 0.212
DTL 13 1.24E-04 0.278
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Table 2
Top 5 associations for synonymous variants with decreasing RSCU scores (8,066 genes total)
Gene # of Loci p-value Corrected p-value
MLST8 6 4.10E-06 0.033
RHOB 4 1.14E-05 0.046
TRMT44 3 5.12E-05 0.122
RCC2 4 6.79E-05 0.122
MOB3B 4 7.56E-05 0.122
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Table 3
Top associations for synonymous variants with increasing RSCU scores (4774 genes total)
Gene # of Loci p-value Corrected p-value
FLG2 9 2.52E-05 0.039
CHD6 6 2.63E-05 0.039
CD244 2 3.48E-05 0.039
FLG-AS1 10 3.95E-05 0.039
SERPINB5 3 4.10E-05 0.039
GTF3C1 3 5.60E-05 0.045
GABRG1 2 1.07E-04 0.073
SRP72 4 1.39E-04 0.083
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Table 4
Top 5 associations for synonymous variants in non-optimal codons (O to NO; 8,401 genes total)
Gene # of Loci p-value Corrected p-value
RHOB 4 1.14E-05 0.096
MLST8 6 6.78E-05 0.246
MSH2 13 1.54E-04 0.246
AKAP3 3 2.08E-04 0.246
RASGRF2 4 2.10E-04 0.246
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Table 5
Top associations for synonymous variants in optimal codons (NO to O; 2,625 genes total)
Gene # of Loci p-value Corrected p-value
DTL 4 4.45E-06 0.012
FLG2 9 2.68E-05 0.028
SERPINB5 3 4.10E-05 0.028
FLG-AS1 10 4.30E-05 0.028
ZNF599 2 9.42E-05 0.049
SRP72 4 1.39E-04 0.056
DLL4 3 1.50E-04 0.056
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